EI
SRNE

EAM Investors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

EAM Investors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-249,028
Closed -$4.39M – 359
2015
Q2 		$4.39M Buy
+249,028
New +$3.2M 0.51% 47

Other funds holding SRNE

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

EAM Investors's SRNE Position: Q3 2015 in Review

EAM Investors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2015, closing a stake of 249,028 shares — an estimated $4.39M sold.

EAM Investors first reported a position in SRNE in Q2 2015 and held it in 1 quarter. The position peaked at $4.39M in Q2 2015. 88 funds tracked by Wall St. Rank hold SRNE as of Q3 2015.

  • EAM Investors reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • EAM Investors sold 249,028 Sorrento Therapeutics, Inc. shares in Q3 2015, an estimated $4.39M.
  • EAM Investors first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • EAM Investors's Sorrento Therapeutics, Inc. position peaked at $4.39M in Q2 2015.
  • 88 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2015.

Based on EAM Investors's 13F filing for Q3 2015, filed 6 Nov 2015.